Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

~32 mi. (Lyon, France, +140 more cities)

Hopital de la Croix-Rousse ( Site 0193)

Hepatocellular Carcinoma

lenvatinib, +2 more drugs

chemotherapy, +2 more types

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

~32 mi. (Lyon, France, +159 more cities)

Centre Leon Berard ( Site 0465)

Superficial Bladder Urothelial Carcinoma

cisplatin, +2 more drugs

chemotherapy, +1 more type

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

~32 mi. (Lyon, France, +131 more cities)

Hôpital Edouard Herriot ( Site 1116)

HER2 Negative

Adenocarcinoma of the Gastroesophageal Junction, +2 more conditions

CAPOX regimen, +3 more drugs

chemotherapy, +2 more types

A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer

~32 mi. (Lyon, France, +202 more cities)

Site FR33003

CLDN18 Expression, +1 more biomarker

Adenocarcinoma of the Gastroesophageal Junction, +1 more condition

modified FOLFOX6 regimen, +1 more drug

chemotherapy, +1 more type

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)

~32 mi. (Lyon, France, +127 more cities)

Centre Leon Berard ( Site 1901)

Hypopharyngeal Squamous Cell Carcinoma, +3 more conditions

lenvatinib, +1 more drug

immunotherapy, +1 more type

Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)

~32 mi. (Lyon, France, +105 more cities)

Centre Leon Berard ( Site 0459)

Colorectal Adenocarcinoma

bevacizumab, +1 more drug

targeted therapy

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

~32 mi. (Lyon, France, +184 more cities)

Centre Leon Berard

RET Fusion

Non-Squamous Non-Small Cell Lung Carcinoma

selpercatinib

targeted therapy

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

~32 mi. (Lyon, France, +103 more cities)

Centre Leon Berard

EGFR Exon 19 Deletion, +1 more biomarker

Non-Small Cell Lung Carcinoma

patritumab deruxtecan

chemotherapy, +1 more type

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

~32 mi. (Lyon, France, +143 more cities)

Centre Leon Berard

RET Mutation

Thyroid Gland Medullary Carcinoma

selpercatinib

targeted therapy

Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

~32 mi. (Lyon, France, +120 more cities)

Centre de Lutte Contre le Cancer - Centre Léon Bérard

FGFR3 A391E, +9 more biomarkers

Urothelial Carcinoma

infigratinib

targeted therapy

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

~32 mi. (Lyon, France, +75 more cities)

Institut d'Hematologie-Oncologie Pediatrique (IHOP) ( Site 0448)

Classical Hodgkin Lymphoma

bleomycin, +9 more drugs

chemotherapy, +2 more types

TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

~32 mi. (Lyon, France, +144 more cities)

Centre Leon Berard

EGFR Exon 20 Insertion

Non-Squamous Non-Small Cell Lung Carcinoma

mobocertinib

targeted therapy